Jazz Pharmaceuticals/JAZZ

$108.37

1.18%
-
1D1W1MYTD1YMAX

About Jazz Pharmaceuticals

Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).

Ticker

JAZZ

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Bruce Cozadd

Employees

2,800

Headquarters

Dublin, Ireland

JAZZ Metrics

BasicAdvanced
$6.91B
Market cap
18.13
P/E ratio
$6.12
EPS
0.63
Beta
-
Dividend rate
$6.91B
0.627
$146.70
$110.09
618.81K
2.236
1.847
136.822
153.022
10.859
2.06%
3.76%
12.16%
4.23%
18.134
1.803
1.848
6.591
4.78%
271.92%
17.5%
13.06%

What the Analysts think about JAZZ

Analyst Ratings

Majority rating from 19 analysts.
Buy

Price Targets

Average projection from 17 analysts.
73.7% upside
High $230.00
Low $121.00
$108.37
Current price
$188.24
Average price target

JAZZ Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
9.29% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$1.01B
4.09%
Net income
$94.1M
-35.9%
Profit margin
9.29%
-38.48%

JAZZ Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 3.17%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$3.95
$4.51
$4.84
$5.02
-
Expected
$4.24
$4.43
$4.93
$5.18
$4.20
Surprise
-6.83%
1.76%
-1.87%
-3.17%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Jazz Pharmaceuticals stock?

Jazz Pharmaceuticals (JAZZ) has a market cap of $6.91B as of April 19, 2024.

What is the P/E ratio for Jazz Pharmaceuticals stock?

The price to earnings (P/E) ratio for Jazz Pharmaceuticals (JAZZ) stock is 18.13 as of April 19, 2024.

Does Jazz Pharmaceuticals stock pay dividends?

No, Jazz Pharmaceuticals (JAZZ) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next Jazz Pharmaceuticals dividend payment date?

Jazz Pharmaceuticals (JAZZ) stock does not pay dividends to its shareholders.

What is the beta indicator for Jazz Pharmaceuticals?

Jazz Pharmaceuticals (JAZZ) has a beta rating of 0.63. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Jazz Pharmaceuticals stock price target?

The target price for Jazz Pharmaceuticals (JAZZ) stock is $188.24, which is 72.27% above the current price of $109.27. This is an average based on projections from 17 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Jazz Pharmaceuticals stock

Buy or sell Jazz Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing